SNDX News and Press, Syndax Pharmaceuticals Inc. From 01/02/24

Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass. , Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer ...

2024-01-02 07:54:28 ET More on Syndax Pharmaceuticals Sizing Up Syndax Pharmaceuticals Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023 Mizuho starts Syndax at buy; cites market potential, cash position Syndax announces proposed $150M publi...

Syndax Highlights Recent Updates and Anticipated 2024 Milestones PR Newswire – BLA submitted for axatilimab in chronic graft-versus-host disease; Syndax exercised option to co-commercialize axatilimab in the U.S. with Incyte – – NDA submitted f...

2023-12-26 21:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-26 11:15:43 ET Summary Syndax Pharmaceuticals, Inc. has experienced a roller coaster ride in the stock market, but is currently up 80% from its lows in October. The company has two candidates in development that are poised to garner FDA approval in 2024 and also just fille...

Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares PR Newswire WALTHAM, Mass. , Dec. 19, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (N...

2023-12-15 05:15:59 ET More on Syndax Pharmaceuticals Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023 Syndax announces proposed $150M public offering of common stock Syndax reports encouraging Phase 1 data for leukemia drug For further det...

Syndax Announces Pricing of $200 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...

2023-12-14 16:04:01 ET More on Syndax Pharmaceuticals Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023 Syndax reports encouraging Phase 1 data for leukemia drug BofA starts ...

Syndax Announces Proposed $150 Million Public Offering of Common Stock PR Newswire WALTHAM, Mass. , Dec. 14, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an inn...